Drug intelligence / Profile preview

Hydrocortisone aceponate

Development stage
Approved
Lead developer
Ecuphar
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Topical, Otic
01

Overview

Hydrocortisone aceponate is a synthetic corticosteroid diester used primarily in veterinary medicine for the topical treatment of inflammatory and pruritic skin conditions (dermatoses) in animals, especially dogs. It is an ester of hydrocortisone (cortisol) with acetic acid and propionic acid, which increases its lipophilicity and enhances skin penetration as well as local retention. The drug acts by binding to the glucocorticoid receptor; the receptor-ligand complex then translocates to the nucleus where it modulates gene expression, leading to anti-inflammatory and immunosuppressive effects. This includes inhibition of phospholipase A2 activity (reducing prostaglandin and leukotriene synthesis), suppression of cyclooxygenase enzymes COX-1/COX-2, decreased vasodilation/capillary permeability, reduced leukocyte migration, and increased production of anti-inflammatory proteins such as lipocortin-1. Hydrocortisone aceponate is approved for veterinary use in the European Union for atopic dermatitis and acute otitis externa in dogs. Developed by Ecuphar.

Brand names
CortavanceEasotic
Other names
hydrocortisone 17-propionate 21-acetatehydrocortisone17-propionate 21-acetatehydrocortisone-17-propionate 21-acetatehydrocortisone aceponate 0.127%
02

Targets

GR (Glucocorticoid receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PLA2 (Phospholipase A2 group IID)

Beyond the preview

Go deeper on Hydrocortisone aceponate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hydrocortisone aceponate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call